Histone deacetylase inhibitors: Anticancer compounds

被引:69
|
作者
Smith, Karen T. [1 ]
Workman, Jerry L. [1 ]
机构
[1] Stowers Inst Med Res, Kansas City, MO 64110 USA
关键词
HDAC; Acetylation; Chromatin; Cancer; Cell cycle; SUBEROYLANILIDE HYDROXAMIC ACID; ESTROGEN-RECEPTOR-ALPHA; CARCINOMA-CELL-LINES; BREAST-CANCER CELLS; PML-RAR-ALPHA; VALPROIC ACID; PROTEASOMAL DEGRADATION; DNA METHYLTRANSFERASE-1; SODIUM-BUTYRATE; HDAC INHIBITORS;
D O I
10.1016/j.biocel.2008.09.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The reversible acetylation of proteins is mediated by histone acetytransferases which acetylate proteins and historic deacetylases that remove the acetyl groups. High levels of histone acetylation are correlated with active genes, while hypoacetylation of histones corresponds with gone repression. Importantly, acetylation also occurs on non-histone proteins all this call affect the activity and stability of these proteins. Aberrant epigenetic changes ate a common hallmark Of tumors and Imbalances in the activities of deacetylases have been associated with cancers. Accordingly, inhibitors to the historic deacetylases are in clinical trials for the treatment of several cancer types. These drugs mediate a number Of molecular changes and ill turn Call induce cell cycle arrest, apoptosis or differentiation of cancer cells while displaying limited toxicity in normal cells. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 50 条
  • [21] The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?
    Taddei, A
    Roche, D
    Bickmore, WA
    Almouzni, G
    EMBO REPORTS, 2005, 6 (06) : 520 - 524
  • [22] Rational development of histone deacetylase inhibitors as anticancer agents: A review
    Acharya, MR
    Sparreboom, A
    Venitz, J
    Figg, WD
    MOLECULAR PHARMACOLOGY, 2005, 68 (04) : 917 - 932
  • [23] The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
    Marks, Paul A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (09) : 1049 - 1066
  • [24] Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
    Villar-Garea, A
    Esteller, M
    INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (02) : 171 - 178
  • [25] Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency
    Pan, Yuan
    Hou, Haodong
    Zhou, Bo
    Gao, Jingyue
    Gao, Feng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 262
  • [26] Life or death? Autophagy in anticancer therapies with statins and histone deacetylase inhibitors
    Yang, Pei-Ming
    Chen, Ching-Chow
    AUTOPHAGY, 2011, 7 (01) : 107 - 108
  • [27] New histone deacetylase inhibitors and anticancer agents from Curcuma longa
    Pakit Kumboonma
    Thanaset Senawong
    Somprasong Saenglee
    Gulsiri Senawong
    La-or Somsakeesit
    Chavi Yenjai
    Chanokbhorn Phaosiri
    Medicinal Chemistry Research, 2019, 28 : 1773 - 1782
  • [28] Oxadiazole derivatives: Histone deacetylase inhibitors in anticancer therapy and drug discovery
    Matore, Balaji Wamanrao
    Banjare, Purusottam
    Guria, Tanmoy
    Roy, Partha Pratim
    Singh, Jagadish
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS, 2022, 5
  • [29] New histone deacetylase inhibitors and anticancer agents from Curcuma longa
    Kumboonma, Pakit
    Senawong, Thanaset
    Saenglee, Somprasong
    Senawong, Gulsiri
    Somsakeesit, La-or
    Yenjai, Chavi
    Phaosiri, Chanokbhorn
    MEDICINAL CHEMISTRY RESEARCH, 2019, 28 (10) : 1773 - 1782
  • [30] An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
    West, Alison C.
    Mattarollo, Stephen R.
    Shortt, Jake
    Cluse, Leonie A.
    Christiansen, Ailsa J.
    Smyth, Mark J.
    Johnstone, Ricky W.
    CANCER RESEARCH, 2013, 73 (24) : 7265 - 7276